BioPharmSolutions Receives Approval for Phase 1 Clinical Trial Plan of Neuropathic Pain Treatment

[Asia Economy Reporter Park Jihwan] Biopharm Solutions, a central nervous system (CNS) drug development company, announced on the 25th that it obtained approval for the clinical trial plan (IND) for the Phase 1 clinical trial of ‘JBPOS501,’ a candidate drug for neuropathic pain treatment, from the Ministry of Food and Drug Safety on the 23rd.

Neuropathic pain refers to a sensory nervous system disorder in which patients experience unbearable severe pain from stimuli that would not cause pain in normal individuals. It is a refractory pain caused by nerve damage or functional abnormalities and is characterized by its long-lasting nature.

Patients with neuropathic pain suffer not only from the pain itself but also from emotional disorders such as sleep disturbances and depression, significantly reducing their quality of life. It can also lead to decreased productivity due to reduced social adaptability, making it a social issue.

According to Biopharm Solutions, the pain-related market is expected to grow at an average annual rate of over 5%, from 23 trillion KRW in 2016 to about 34 trillion KRW in 2023. Among this, the market size for neuropathic pain is expected to reach 4 trillion KRW this year.

JBPOS501, developed by Biopharm Solutions, demonstrated broad pain reduction effects and safety in preclinical experiments conducted on laboratory rats. Although the company received IND approval for Phase 1 clinical trials from the U.S. Food and Drug Administration (FDA) last year, it decided to conduct clinical trials domestically first due to its drug development strategy.

Through this Phase 1 clinical trial, Biopharm Solutions plans to primarily evaluate the safety of treatment for neuropathic pain. Additionally, it plans to analyze the potential for expanding indications to postpartum depression and epilepsy treatments.

Choi Yongmoon, CEO of Biopharm Solutions, stated, "JBPOS501 is not only a treatment for neuropathic pain but was also selected for the Red Book, the highest-rated drug evaluation related to epilepsy treatment by the NIH ESTP (Epilepsy Therapy Screening Program), certifying its excellence. As the global epilepsy treatment market is also rapidly growing, we expect related benefits as well."

This content was produced with the assistance of AI translation services.